Who We Are

Lucence is a genomic medicine company focused on personalizing cancer care. We invent novel liquid biopsy tests to achieve early cancer detection and improve treatment selection. Headquartered in Singapore with offices in San Francisco, Hong Kong, and Suzhou, we deliver our clinical services worldwide through a CLIA-certified and CAP-accredited laboratory.

Vision

A world without avoidable cancer deaths.

Mission

To achieve early cancer detection, better treatment and less suffering through deep genome intelligence.

Our Story

We see the fight against cancer as a mission. If we can deliver early detection for all cancers to achieve cure, that is something worth our time, our energy, everything.

Dr Min-Han Tan Founding CEO and Medical Director

The story of Lucence began in 1999, when our founder Dr Min-Han Tan (Han) was a medical resident at the university cancer center in Singapore. There he witnessed great suffering, but also saw the ability of modern medicine to alleviate unnecessary pain and distress. This formative experience motivated him to focus his life and career on understanding how to fight and defeat cancer through a deep understanding of the human genome. Han believes that oncology exists where bedside medicine, high technology, deep research and profound spirituality intersect.

Han first completed his medical oncology specialist training. He then went on to pursue his PhD in cancer genetics at the Karolinska Institute, Sweden and National University of Singapore. To seek deeper understanding on genomic medicine, Han joined the Cleveland Clinic in the United States as a research scholar, where he was awarded both the Lee Foundation and Ambrose Monell Cancer Genomic Medicine Fellowships. At the Cleveland Clinic, he and Professor Charis Eng published landmark data models on cancer risk in hereditary breast and thyroid cancers. This work continues to guide the international cancer community in patient care today.

In 2011, Han joined the Agency for Science, Technology and Research (A*STAR) to lead the Laboratory of Systems Medicine and focus on building better genomic technology for cancer patients. Over the next 5 years, Han and his team made key discoveries on the nature of circulating tumor DNA and circulating tumor cells by applying innovative laboratory and machine-learning technologies. His discovery of the circulating tumor-endothelial cluster transformed the liquid biopsy field and overturned decades of scientific dogma. This research led to improved non-invasive screening and profiling of cancer using blood testing.

Han founded Lucence in 2016 to deliver his genomic technology from the laboratory to the world where it was most needed. Lucence’s vision is a world without avoidable cancer deaths through early cancer detection and better treatment selection. The company’s AmpliMARK™ sequencing technology is used in its flagship liquid biopsy test LiquidHALLMARK® to detect cancer-causing mutations and viruses. Its AI platform SunTzu.AI™ centralizes genomic intelligence and maps cancer-fighting strategies for each patient.  

In 2017, Lucence raised US$9.2 million in seed funding, one of the largest seed investments raised by a biomedical start-up in Asia Pacific. Today, Lucence’s liquid biopsy tests are available across Asia to help doctors reduce the pain and sufferings of cancer patients.

Achieving a world without avoidable cancer deaths through genomic intelligence is at the core of everything Lucence does.

Read More

Milestones

March
2016

Company founded

August
2017

Raised US$9.2 million seed funding

April
2018

Laboratory receives ISO:15189 accreditation

May
2018

Lucence sets up first overseas office in Hong Kong

April
2019

Company expands to 2 cities in San Francisco and Suzhou

September
2019

Lucence receives CAP and CLIA accreditation

Our Investors

We are a venture-backed company with the mission to fight cancer through earlier diagnosis and treatment. We are supported by a group of like-minded investors that understands how great technology is nurtured and developed, the positive impact it can have on lives, and the real difference it can make to humanity.

Our Partners

We partner with healthcare providers and medical laboratories to deliver our cancer diagnostic services to physicians. We also collaborate with hospitals, research institutes and universities to conduct studies that advance the field of genomic medicine.

Our Team Leaders

Min-Han Tan CEO and Medical Director
Yukti Choudhury Chief Technology Officer
Pan Zhao Chief Commercial Officer
Kevin Goh Chief Financial Officer
Wai Min Phyo Director,
Assay Development
Jess Vo Director,
Operations
Jack Challis Director,
Healthcare Analytics
Hilary Kan Regional Director and Product Management Head
Hao Chen Director,
Informatics
Jamen Loh Director,
Business Development
Benson Lim General Counsel
Aster Ding Market Lead (China)
Daniel Tan Kian Hin NGS Service Lead
Yvonne Sim Manager,
People & Organisational Development
Hilda Tan Manager,
Business Development
Yong Herng Low Laboratory Manager
Careers

Join Our Team

Lucence is a fast-growing genomic medicine company with offices in Singapore, San Francisco, Hong Kong and Suzhou.

We have assembled a dynamic team of physicians, scientists, geneticists, bioinformaticians and data analysts who are passionate about the work we do here to improve cancer care. We come from different backgrounds and nationalities but are focused on a single mission – to fight cancer and save lives.

Join our team to transform the way we fight cancer.
Click here to view our open positions.

Need Help?